
SLA Pharma AG & KD Pharma Group COVID-19 Clinical Trial Approved
NewsBIOGGIO, SWITZERLAND – April 14, 2020 – The KD Pharma Group (“KD Pharma”) and its partner, SLA Pharma AG (“SLA”), announced that its new drug candidate EPAspireTM is shortly entering clinical trials as a promising candidate to treat…

Meeting with the FDA in October 2019 for ALFA™
News
SLA Pharma AG are meeting with the FDA in October 2019 to discuss a new drug application for our late stage development ALFA™ for the treatment of familial adenomatous polyposis (FAP). ALFA™ is currently undergoing clinical studies in…

SLA Pharma AG at BIO-Europe 2019
News
SLA Pharma AG are attending the annual Bio-Europe conference in Hamburg, Germany from November 11th-13th 2019.
The BIO-Europe conference is a great opportunity to meet and connect with hundreds of pharmaceutical companies, one-to-one. SLA…

Alfa – Pharmacist information
Pharmacist infoIndicated for the treatment of familial adenomatous polyposis & ulcerative colitis.

Ortem – Pharmacist information
Pharmacist infoIndicated for the treatment of pilonidal sinus disease.

Anotop clinical trials
Clinical trialsIndicated for the treatment of chronic anal fissures.

ALFA clinical trials
Clinical trialsIndicated for the treatment of familial adenomatous polyposis & ulcerative colitis.

Ortem clinical trials
Clinical trialsIndicated for the treatment of pilonidal sinus disease.
